跳至主要内容
临床试验/NCT03474757
NCT03474757已完成不适用

Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases - TREND Colombia

Bayer1 个研究点 分布在 1 个国家目标入组 10,528 人开始时间: 2018年2月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
10,528
试验地点
1
主要终点
Sex

研究概览

简要总结

This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting.
  • Non valvular Atrial Fibrillation (NVAF) Patients
  • aged ≥18 years
  • at least one year of enrollment in the Audifarma database
  • one year since first encounter with healthcare provider will be included in the study

排除标准

  • Patients with any record of index drug prescription prior to the enrolment period.
  • Patients who qualify as members of more than one cohort study on the same day

结局指标

主要结局

Sex

时间窗: At Baseline

Proportion of Naive to non-naive patient

时间窗: At Baseline

Duration of treatment

时间窗: Up to 6 years

Discontinuation

时间窗: Up to 6 years

Age

时间窗: At Baseline

Co-morbidity

时间窗: At Baseline

Healthcare utilization

时间窗: Up to 2 years

Primary Care Physicians visits, Outpatient visits and Hospital admissions

Dose at first prescription

时间窗: Up to 6 years

Switch to another study drug

时间窗: Up to 6 years

次要结局

  • Time trends of usage of study medications(Up to 6 years)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验